NeoGenomics (NEO)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$0.25 (+1.36%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

Relative Strength Index (RSI)

- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.

- The RSI is calculated using the following formula:

RSI = 100 - (100 / (1 + RS))

Where RS is the ratio of the average gains to the average losses over a specified period.

- The default time period used is 14 days.

- RSI values range between 0 and 100.

RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)

RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)

RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.

About

Business overview of NeoGenomics (NEO)
NeoGenomics Inc operates a network of cancer-focused genetic testing laboratories in the United States as well as a laboratory in Switzerland. The company operates into two segments namely Clinical Services and Advanced Diagnostics. It offers types of genetic and molecular testing services namely Cytogenetics, Fluorescence In-Situ Hybridization, Flow cytometry, Immunohistochemistry, Molecular testing, Pathology consultation. Advanced Diagnostics segment supports pharmaceutical firms in their drug development programs by supporting various clinical trials and research. For Clinical Services, Its specialized diagnostic services are performed based on an online test order or a written test requisition form. The company generates majority of its revenue from Clinical Services.

Key Insights

Critical company metrics and information

  • Share Price

    $18.56

  • Market Cap

    $2.38 Billion

  • Total Outstanding Shares

    128.36 Million Shares

  • Total Employees

    2,100

  • Dividend

    No dividend

  • IPO Date

    January 25, 1996

  • SIC Description

    Services-testing Laboratories

  • Primary Exchange

    NASDAQ

  • Type

    Common Stock

  • Phone Number

    (239) 768-0600

  • Address

    9490 neogenomics way, Fort myers, FL, 33912

  • Homepage

    https://www.neogenomics.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow From Operating Activities, Continuing$15.01 Million
Net Cash Flow, Continuing$55.75 Million
Net Cash Flow From Financing Activities, Continuing$5.23 Million
Net Cash Flow From Financing Activities$5.23 Million
Net Cash Flow From Investing Activities, Continuing$35.52 Million
Net Cash Flow From Operating Activities$15.01 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations After Tax$-77.73 Million
Income Tax Expense/Benefit$-2.10 Million
Diluted Average Shares$126.64 Million
Net Income/Loss Attributable To Parent$-77.73 Million
Benefits Costs and Expenses$723.95 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Assets$1.64 Billion
Current Assets$590.24 Million
Liabilities$732.90 Million
Equity Attributable To Parent$908.21 Million
Noncurrent Assets$1.05 Billion
Current Liabilities$296.41 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
Earnings CalendarNews ArticlesAbout UsPrivacy & Cookies Info

ⓒ 2025 Financhle. All Rights Reserved.